Notable
U16 · Relapsed or Refractory Non-Hodgkin's Lymphoma
Primary completion pushed from Dec 31, 2024 to Dec 31, 2028
Also in this update: Study completion pushed from Dec 31, 2026 to Dec 31, 2030
Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdPhase 1/2 NCT05768529 Registry history of NCT05768529 on ClinicalTrials.gov (opens the registry)